Major trial tests new antibody drug for hospitalized COVID-19 patients
NCT ID NCT04315948
First seen May 21, 2026 · Last updated Jun 20, 2026 · Updated 5 times
Summary
This large, completed trial tested several potential COVID-19 treatments in over 1,500 hospitalized adults across Europe. Earlier drugs like remdesivir and hydroxychloroquine were dropped after showing no benefit. The current phase is testing a new antibody combination called AZD7442 against a placebo, alongside standard care. The goal is to see if it improves patient recovery and reduces the need for oxygen or ventilation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONA VIRUS INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AP-HP Hôpital Bicêtre
Le Kremlin-Bicêtre, 94270, France
-
APHP - Hôpital Bichat Claude Bernard
Paris, 75018, France
-
APHP - Hôpital Cochin
Paris, 75014, France
-
APHP - Hôpital Lariboisière
Paris, 75010, France
-
APHP - Hôpital Necker
Paris, 75015, France
-
APHP - Hôpital Saint Antoine
Paris, 75012, France
-
APHP - Hôpital Saint Louis
Paris, 75010, France
-
APHP - Hôpital Tenon
Paris, 75020, France
-
APHP - Hôpital Universitaire Pitié Salpêtrière
Paris, 75013, France
-
APHP - hôpital Henri-Mondor
Créteil, 94010, France
-
APHP- Hôpital Européen Georges-Pompidou
Paris, 75015, France
-
Akershus Unniversity Hospital
Oslo, Norway
-
CH Bretagne Atlantique
Vannes, 56000, France
-
CH Bretagne Atlantique
Vannes, France
-
CH Cornouaille
Quimper, France
-
CHU APHP Ambroise-Paré
Boulogne-Billancourt, France
-
CHU Nîmes
Nîmes, France
-
CHU Poitiers
Poitiers, France
-
CHU de Reims
Reims, 51100, France
-
CHULN- Hospital de Santa Maria
Lisbon, Portugal
-
Centre Hospitalier Andrée Rosemon
Cayenne, 97306, France
-
Centre Hospitalier Annecy Genevois
Épagny, 74370, France
-
Centre Hospitalier Luxembourg
Luxembourg, L-1210, Luxembourg
-
Centre Hospitalier Regional Metz-Thionville
Ars-Laquenexy, 57085, France
-
Centre Hospitalier Régional Universitaire de Besançon
Besançon, 25000, France
-
Centre Hospitalier Régional Universitaire de Lille
Lille, 59000, France
-
Centre Hospitalier Régional Universitaire de Strasbourg
Strasbourg, 67000, France
-
Centre Hospitalier Régional et Universitaire de Nancy
Nancy, 54000, France
-
Centre Hospitalier Universitaire Amiens-Picardie
Amiens, 80054, France
-
Centre Hospitalier Universitaire Dijon-Bourgogne
Dijon, 21000, France
-
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, 33000, France
-
Centre Hospitalier Universitaire de Martinique
Fort de France, 97261, France
-
Centre Hospitalier Universitaire de Montpellier
Montpellier, 34000, France
-
Centre Hospitalier Universitaire de Nantes
Nantes, 44000, France
-
Centre Hospitalier Universitaire de Rennes
Rennes, 35033, France
-
Centre Hospitalier Universitaire de Saint Etienne
Saint-Etienne, 42055, France
-
Centre Hospitalier Universitaire de Toulouse
Toulouse, 31000, France
-
Centre Hospitalier Universitaire de Toulouse
Toulouse, 31300, France
-
Centre Hospitalier Universitaire de Tours
Tours, 37000, France
-
Centre Hospitalier de Tourcoing
Tourcoing, 59208, France
-
Centre Hospitalo-Universitaire de Grenoble
La Tronche, 38700, France
-
Centre Hospitalo-Universitaire de Nice
Nice, 06000, France
-
Centro Hospitalar Universitário de São João, EPE
Porto, Portugal
-
Evaggelismos General Hospital
Athens, Greece
-
General University Hospital of Patras
Pátrai, Greece
-
Groupe Hospitalier de la Région de Mulhouse Sud Alsace
Mulhouse, 68100, France
-
Hopital DELAFONTAINE
Saint-Denis, 93200, France
-
Hospices Civil
Colmar, France
-
Hospices Civils de Lyon
Lyon, 69000, France
-
Hospital de Cascais
Cascais, Portugal
-
Hôpital Erasme - Cliniques universitaires de Bruxelles
Brussels, 1070, Belgium
-
Hôpital La Citadelle
Liège, 4000, Belgium
-
Hôpital Paris Saint-Joseph et Marie Lannelongue
Paris, 75014, France
-
Hôpital Saint Luc
Brussels, 1200, Belgium
-
Hôpital d'Instruction des Armées BEGIN
Saint-Mandé, 94160, France
-
Hôpitaux Robert Schuman
Luxembourg, L-2450, Luxembourg
-
Kepler Universitätsklinikum Linz
Linz, Austria
-
Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Salzburg, 5020, Austria
-
Lovisenberg Diaconal Hospital
Oslo, Norway
-
Medizinische Universität Innsbruck
Innsbruck, 6020, Austria
-
Oslo University Hospital
Oslo, Norway
-
Pôle Hospitalier Jolimont / site de Mons-Warquignies
Mons, Belgium
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Remdesivir, lopinavir/ritonavir, hydroxychloroquine, interferon beta-1a, and AZD7442 (a monoclonal antibody combination)
What this could lead to
If successful, AZD7442 could become a standard treatment to help hospitalized COVID-19 patients recover faster and reduce severe outcomes.
What could go wrong
This is an early-stage analysis for AZD7442 within a larger trial; previous drugs tested were stopped due to lack of benefit. Results may not apply to all patients or variants.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.